Updated: Jul 22, 2020
Sanofi SA’s Genzyme unit cannot block a former employee from joining BioMarin Pharmaceutical Inc, where he would help launch a gene therapy treatment for hemophilia that would compete with a drug his ex-employer markets, a Massachusetts judge has ruled.
Suffolk County Superior Court Judge Janet Sanders in Boston on Friday ruled Genzyme had failed to show why a preliminary injunction enforcing a non-compete agreement Keith Hanglin signed was needed to protect any of its legitimate business interests.